Osimertinib and Chemotherapy for EGFR-mutated Metastatic Lung Adenocarcinoma

This clinical trial is designed to explore a new treatment approach for patients with a specific type of lung cancer, known as metastatic EGFR-mutated lung adenocarcinoma. The study focuses on patients who traditionally have a poor prognosis. The goal is to determine how effective a combination of standard chemotherapy drugs (pemetrexed with either carboplatin or cisplatin) and a medication called osimertinib is in improving outcomes for these patients. This is important because finding better treatment methods could lead to longer survival and improved quality of life for individuals with this challenging condition. During the study, participants will first receive osimertinib and have their blood tested for specific cancer-related markers called EGFR mutations. After about three weeks of taking osimertinib, the blood test is repeated to see if there are changes in these markers. Participants who meet the criteria will then start chemotherapy within six weeks of beginning osimertinib. Researchers will track several outcomes, such as how long patients live without their disease getting worse and how well the cancer responds to treatment. The study also looks at how long patients continue the treatment and whether the cancer markers in the blood decrease, which could indicate a positive response to the therapy.